- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | ADALTA LIMITED: Notification of cessation of securities - 1AD | 3 | ASX | ||
| 01.04. | ADALTA LIMITED: BZDS1901 clinical update | 1 | ASX | ||
| ADALTA Aktie jetzt für 0€ handeln | |||||
| 26.03. | ADALTA LIMITED: AdCella and SHcell hold first JDC meeting | - | ASX | ||
| 20.03. | Daily Special: Atlantic Lithium, AdAlta, Brightstar Resources | 4 | Finance News Network | ||
| 20.03. | AdAlta Secures Canadian Patent for Anti-Fibrotic Drug AD-214 | 2 | Finance News Network | ||
| 19.03. | ADALTA LIMITED: New AD-214 patent granted | - | ASX | ||
| 17.03. | ADALTA LIMITED: Fadi Diab to join AdAlta Board | - | ASX | ||
| 17.03. | ADALTA LIMITED: Initial Director's Interest Notice (FD) | - | ASX | ||
| 03.03. | ADALTA LIMITED: AdCella expands clinical advisory board | - | ASX | ||
| 25.02. | ADALTA LIMITED: AdCella Clinical Advisory Board convened | - | ASX | ||
| 19.02. | ADALTA LIMITED: Half Yearly Report and Accounts | - | ASX | ||
| 03.02. | ADALTA LIMITED: ANZ Biologics Festival presentation | - | ASX | ||
| 29.01. | ADALTA LIMITED: Cleansing Notice | - | ASX | ||
| 29.01. | ADALTA LIMITED: Application for quotation of securities - 1AD | - | ASX | ||
| 29.01. | ADALTA LIMITED: Application for quotation of securities - 1AD | - | ASX | ||
| 29.01. | ADALTA LIMITED: Quarterly Appendix 4C and Activities Report | - | ASX | ||
| 20.01. | ADALTA LIMITED: AdCella milestones and regulatory progress | - | ASX | ||
| 14.01. | ADALTA LIMITED: East to West webinar presentation - BZDS1901 | - | ASX | ||
| 13.01. | ADALTA LIMITED: Upcoming investor webinar | 2 | ASX | ||
| 13.01. | ADALTA LIMITED: Proposed issue of securities - 1AD | - | ASX |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,350 | +0,91 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ERASCA | 16,310 | -4,23 % | What's Driving Erasca (ERAS)'s Nearly 355% YTD Return | ||
| BIONTECH | 82,30 | +1,04 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 3,050 | +12,13 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,140 | +9,80 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 316,75 | +0,71 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed... ► Artikel lesen | |
| NURIX THERAPEUTICS | 15,910 | -0,75 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| EVOTEC | 4,700 | +3,84 % | Evotec nominiert ehemaligen Bayer-Manager als Aufsichtsratschef | Evotec SE hat Dieter Weinand als Kandidaten für den Vorsitz des Aufsichtsrats nominiert. Die Hauptversammlung am 11. Juni 2026 soll über seine Wahl abstimmen. Weinand war zuvor unter anderem Vorstandsmitglied... ► Artikel lesen | |
| MAZE THERAPEUTICS | 27,420 | +2,77 % | Zifo Technologies: Zifo and Maze Therapeutics Partner to Power Precision Medicine | SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc have... ► Artikel lesen | |
| CG ONCOLOGY | 67,67 | -0,03 % | CG Oncology, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 21,540 | +7,92 % | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings | ||
| ADMA BIOLOGICS | 10,370 | +6,91 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,500 | +0,38 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| TYRA BIOSCIENCES | 35,610 | +0,99 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 5,200 | +0,58 % | Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update | In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was... ► Artikel lesen |
ADALTA LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,002 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADALTA LIMITED finden Sie auf Wallstreet Online.